GI NURSES CONNECT expert Natasha Pinheiro (USA) discusses the increasing prevalence of young-onset colorectal cancer from the nurse's perspective. She reviews the aetiology of the disease, diagnosis, treatment and special considerations for care in this younger age group.

Hi everyone, my name is Natasha Pinheiro. I'm a Nurse Practitioner in New York City and I'm here today on behalf of GI NURSES CONNECT. I'm talking to you about young onset colorectal cancer.

 

In the past few years we've been seeing an increased incidence in early onset colorectal cancers. We started to see this jump in numbers, starting in the 1960s and then a vastly precipitous jump from 1970 to present. Initially we were thinking this was more of a Western based increase, but we are seeing these numbers and this incidence increase worldwide in the past decade.

 

And when we talk about young onset, we're talking about the age group of 20 to 49. Average onset colorectal is usually designated at age 50 and above.

 

Early onset colorectal cancer has a complex aetiology and it's probably related to a variety of factors, one being dietary intake, an increase in proteins fats, altered gut bacteria, host disease sometimes, metabolic syndrome, obesity and other biological effects.

 

Young onset and average onset colorectal cancers are still predominantly sporadic in nature, which means that there is not necessarily any overreaching underlying pre-existing condition, they tend to just be found.

 

Presenting symptoms and clinical characteristics for the early onset population and the average onset population tend to still be the same. We're not really seeing any difference in how these patients present with symptoms and the characteristics of their disease once diagnosed. We are seeing that the highest incidence in young onset and average onset still tends to be left sided colon tumours.

 

The other thing that we're finding is that the vast majority of young onset patients are being diagnosed with later stage disease, at Stage 3 or Stage 4, for a variety of reasons. One is that this population tends to wait longer before seeking medical attention and even when they do seek medical attention because of their age, they end up seeing two or more physicians before they are properly diagnosed with  colorectal cancer.

 

When we're looking at outcomes of treatment or outcomes of the disease management, there is no real difference in the average onset and the young onset groups. What's really important to keep in mind is that we should be treating these patients and these diseases, based on their staging and not their age.

 

Another important thing to think about with our young onset patients is that they have very specific psychosocial needs that are somewhat different than our average onset patient. We're looking at people that are now at the age of starting families, starting careers. So they have different family needs, they have different needs for career, they are at a different part of their lives, so we really have to take a larger or more interdisciplinary approach in that we have to have the nurses on board, we have to have social work, we have to have psych services. Their needs are very different than the patients that we're seeing over the age of 50 that we have been traditionally treating over the years.

 

If you need to have any further review of this information, we have a slide deck that's available on our website. Thank you.  Have a great day.

Natasha A. Pinheiro is an adult-gerontological primary care nurse practitioner working with the solid tumor gastrointestinal medical oncology group at Memorial Sloan Kettering Cancer Center in New York. She completed her Bachelor Science in nursing from New York University and her masters of science in nursing, adult nurse practitioner form Long Island University. Ms. Pinheiro specializes in the medical management of patients with gastrointestinal cancers, focusing on colorectal cancers with hepatic arterial infusion pump therapy, upper GI and hepatobiliary cancers. She has served on multiple HCC advisory boards and has been a member of the Nursing Advisory Board of the Cholangiocarcinoma Foundation.
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI NURSES CONNECT

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
The emerging role of artificial intelligence in precision oncology

Expert opinion on the clinical application of artificial intelligence (AI)

Experts
Prof. Albrecht Stenzinger
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
BRAF-mutated CRC: from testing to treatment

Medical experts share insights and review key clinical trials

Experts
Prof. Sebastian Stintzing, Dr Thomas Winder
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre. This content is not intended for HCPs within the UK.
other Other
Oncology 
Biomarker testing in NSCLC: patient and caregiver awareness and understanding

Findings from a global survey presented in a poster at ESMO 2024

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr. Rodrigo Paredes, Amy Moore, Anne-Marie Baird, Shani Shilo
Endorsed by
LUNGevity
Lung Cancer Europe IASLC
The Israeli Lung Cancer Foundation ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Ipsen
conference-update Conference update
Oncology 
ESMO 2024: New data on GI, lung, HCC, breast and GU cancers

Renowned medical experts share their insights into new data presented at ESMO 2024

  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024

animated-video Animated Video

Episode

1

of 1

episode
Oncology 
Precision oncology in prostate cancer: tips for optimal genomic testing

From sample collection through to diagnostic modalities 

Experts
Dr Alexander Wyatt
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.